Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 11/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 10/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.38 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24158191 | 0.95 | EPHA2 (0.53) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL19003386 | 0.95 | PTGER2 (0.53) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL19003384 | 0.95 | EGFR (0.58) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL23598429 | 0.95 | EGFR (0.58) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL23598433 | 0.94 | PTGER2 (0.58) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL24157987 | 0.93 | PTGER2 (0.61) | PTGER2EGFREPHA2NFKBIAAKT1 | |
| SCHEMBL19003326 | 0.92 | EPHA2 (0.56) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL23598624 | 0.91 | EPHA2 (0.56) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL24157890 | 0.91 | PTGER2 (0.55) | PTGER2EGFREPHA2SSTR5SSTR2 | |
| SCHEMBL19003383 | 0.91 | PTGER2 (0.57) | PTGER2EGFREPHA2SSTR5SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214835-B1 | Methods and compositions for diagnosis and management of neurodegerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214835-B1 | Methods and compositions for diagnosis and management of neurodegerative diseases | PSEN2, CLN6, PSEN1 | PTGER2 3674/4885EGFR 3609/4885EPHA2 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.